Centene (CNC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Centene is a dominant, diversified insurer with strong positions in Medicaid, ACA, and Medicare Part D, serving nearly 29 million members. Q1 2025 results exceeded expectations, with robust revenue growth, improved margins, and management raising full-year revenue guidance. Valuation models indicate a fair value of $60 per share, offering 9% upside; downside risk is limited, and FCF assumptions are conservative.
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Centene offers strong revenue and earnings growth, coupled with a large national membership base and attractive valuation. Despite these positives, the stock has underperformed in recent years, prompting further investigation. The primary issue is CNC's persistent struggle to meet average industry quality measures in its health plans.
CNC remains well-poised for growth on improved premiums, a well-performing Commercial Marketplace business, strategic divestitures and sound cash reserves.
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
It has been a turbulent start to the year for the healthcare industry, as concerns about major cuts to Medicare and Medicaid coincide with the impact of tariffs on supplies and many other variables. Nonetheless, healthcare stocks have fared well compared to the energy and information technology sectors.
Centene (CNC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.